- ———. 2006. The Medicare Prescription Drug Benefit Fact Sheet.
Paper not yet in RePEc: Add citation now
- ———. 2007a. The Medicare Prescription Drug Benefit Fact Sheet.
Paper not yet in RePEc: Add citation now
- ———. 2007b. Medicare Spending and Financing Fact Sheet.
Paper not yet in RePEc: Add citation now
- ———. 2010. The Medicare Prescription Drug Benefit Fact Sheet.
Paper not yet in RePEc: Add citation now
- ———. 2012. “Physician Agency and Adoption of Generic Pharmaceuticals.†American Economic Review 102 (6): 2826–58.
Paper not yet in RePEc: Add citation now
Acemoglu, Daron, and Amy Finkelstein. 2008. “Input and Technology Choices in Regulated Industries: Evidence from the Health Care Sector.†Journal of Political Economy 116 (5): 837–80.
- Alpert, Abby. 2012. “The Anticipatory Effects of Medicare Part D on Drug Utilization.†Working Paper, April.
Paper not yet in RePEc: Add citation now
Anderson, Michael L., Carlos Dobkin, and Tal Gross. 2014. “The Effect of Health Insurance on Emergency Department Visits: Evidence from an Age-Based Eligibility Threshold.†Review of Economics and Statistics 96 (1): 189–95.
- Arrow, Kenneth J. 1963. “Uncertainty and the Welfare Economics of Medical Care.†The American Economic Review 53 (5): 941–73.
Paper not yet in RePEc: Add citation now
Blume-Kohout, Margaret E, and Neeraj Sood. 2013. “Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development.†Journal of Public Economics 97 (January): 327–36.
- Briesacher, Becky A, Yanfang Zhao, Jeanne M Madden, Fang Zhang, Alyce S Adams, Jennifer Tjia, Dennis Ross-Degnan, Jerry H Gurwitz, and Stephen B Soumerai. 2011. “Medicare Part D and Changes in Prescription Drug Use and Cost Burden: National Estimates for the Medicare Population, 2000 to 2007.†Medical Care 49 (9): 834–41.
Paper not yet in RePEc: Add citation now
Carrera, Mariana, Dana Goldman, and Geoffrey Joyce. 2013. “Heterogeneity in Cost-Sharing and Cost-Sensitivity, and the Role of the Prescribing Physician.†NBER Working Paper Series, no. 19186 (June).
Chalkley, Martin, and James M. Malcomson. 1998. “Contracting for Health Services When Patient Demand Does Not Reflect Quality.†Journal of Health Economics 17 (1): 1–19.
- Charlson, Mary E., Peter Pompei, Kathy L. Ales, and C.Ronald MacKenzie. 1987. “A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation.†Journal of Chronic Diseases 40 (5): 373–83.
Paper not yet in RePEc: Add citation now
- Chay, Kenneth Y., Daeho Kim, and Shailender Swamina. 2010. “Medicare, Hospital Utilization and Mortality: Evidence from the Program’s Origins.†Working Paper.
Paper not yet in RePEc: Add citation now
- Congressional Budget Office (CBO). 2009. Promotional Spending for Prescription Drugs. http://www.cbo.gov/sites/default/files/12-02-drugpromo_brief.pdf.
Paper not yet in RePEc: Add citation now
Dalen, Dag Morten, Enrico Sorisio, and Steinar Strom. 2010. “Choosing Among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?†Working Paper, October.
Ellis, Randall P., and Thomas G. McGuire. 1986. “Provider Behavior under Prospective Reimbursement.†Journal of Health Economics 5 (2): 129–51.
- Engelberg, Joseph, Christopher A. Parsons, and Nathan Tefft. 2013. “First, Do No Harm: Financial Conflicts in Medicine.†Working Paper, January.
Paper not yet in RePEc: Add citation now
- Federman, Alex D. 2004. “Don’t Ask, Don't Tell: The Status of Doctor-Patient Communication about Health Care Costs.†Archives of Internal Medicine 164 (16): 1723–24.
Paper not yet in RePEc: Add citation now
Feldstein, Martin S. 1970. “The Rising Price of Physicians’ Services.†The Review of Economics and Statistics 52 (2): 121–33.
Grembi, Veronica, Tommaso Nannicini, and Ugo Troiano. 2011. “Do Fiscal Rules Matter? A Difference-in-Discontinuities Design.†Working Paper, February.
Ho, Kate, and Ariel Pakes. 2013. “Hospital Choices, Hospital Prices and Financial Incentives to Physicians.†NBER Working Paper Series, no. 19333 (August).
Iizuka, Toshiaki. 2007. “Experts’ Agency Problems: Evidence from the Prescription Drug Market in Japan.†The Rand Journal of Economics 38 (3): 844–62.
Kaestner, Robert, and Nasreen Khan. 2012. “Medicare Part D and Its Effect on the Use of Prescription Drugs and Use of Other Health Care Services of the Elderly.†Journal of Policy Analysis and Management 31 (2): 253–79.
Kaestner, Robert, Cuiping Long, and G. Caleb Alexander. 2014. “Effects of Prescription Drug Insurance on Hospitalization and Mortality: Evidence from Medicare Part D.†NBER Working Paper Series, no. 19948 (February).
- Ketcham, Jonathan D, and Kosali I Simon. 2008. “Medicare Part D’s Effects on Elderly Patients' Drug Costs and Utilization.†The American Journal of Managed Care 14 (11 Suppl): SP14– 22.
Paper not yet in RePEc: Add citation now
Lee, David S, and Thomas Lemieux. 2010. “Regression Discontinuity Designs in Economics.†Journal of Economic Literature 48 (2): 281–355.
- Lichtenberg, Frank R, and Shawn X Sun. 2007. “The Impact of Medicare Part D on Prescription Drug Use By the Elderly.†Health Affairs (Project Hope) 26 (6): 1735–44.
Paper not yet in RePEc: Add citation now
- Liu, Frank Xiaoqing, G Caleb Alexander, Stephanie Y Crawford, A Simon Pickard, Donald Hedeker, and Surrey M Walton. 2011. “The Impact of Medicare Part D on Out-of-Pocket Costs for Prescription Drugs, Medication Utilization, Health Resource Utilization, and Preference-Based Health Utility Utility.†Health Services Research 46 (4): 1104–23.
Paper not yet in RePEc: Add citation now
Liu, Ya-Ming, Yea-Huei Kao Yang, and Chee-Ruey Hsieh. 2009. “Financial Incentives and Physicians’ Prescription Decisions on the Choice between Brand-Name and Generic Drugs: Evidence from Taiwan.†Journal of Health Economics 28 (2): 341–49.
Lu, Fangwen. 2014. “Insurance Coverage and Agency Problems in Doctor Prescriptions: Evidence from a Field Experiment in China.†Journal of Health Economics 106 (January): 156–67.
Lundin, Douglas. 2000. “Moral Hazard in Physician Prescription Behavior.†Journal of Health Economics 19 (5): 639–62.
McCrary, Justin. 2008. “Manipulation of the Running Variable in the Regression Discontinuity Design: A Density Test.†Journal of Econometrics 142 (2). Elsevier: 698–714.
- Nguyen, Ha. 2011. “The Principal-Agent Problems in Health Care: Evidence from Prescribing Patterns of Private Providers in Vietnam.†Health Policy and Planning 26 (suppl_1): i53– 62.
Paper not yet in RePEc: Add citation now
Pauly, Mark. 1980. Doctors and Their Workshops: Economic Models of Physician Behavior. NBER Books. National Bureau of Economic Research, Inc.
- Roth, Martin S. 1996. “Patterns in Direct-to-Consumer Prescription Durg Print Advertising and Their Public Policy Implications.†Journal of Public Policy & Marketing 15 (1): 63–75.
Paper not yet in RePEc: Add citation now
- Sacks, Daniel W. 2013. “Physician Agency , Compliance , and Patient Welfare : Evidence from Anti-Cholesterol Drugs.†Working Paper.
Paper not yet in RePEc: Add citation now
- Stern, Scott, and Manuel Trajtenberg. 1998. “Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking.†NBER Working Paper Series, no. 6851 (December).
Paper not yet in RePEc: Add citation now
- The Henry J. Kaiser Family Foundation. 2003. The Medicare Prescription Drug Benefit Fact Sheet.
Paper not yet in RePEc: Add citation now
- Vakratsas, Demetrios, and Tim Ambler. 1999. “How Advertising Works: What Do We Really Know?†Journal of Marketing 63 (1): 26–43.
Paper not yet in RePEc: Add citation now
Weisbrod, Burton A. 1991. “The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment.†Journal of Economic Literature 29 (2): 523–52.
- Yin, Wesley, Anirban Basu, James X Zhang, Atonu Rabbani, David O Meltzer, and G Caleb Alexander. 2008. “The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures.†Annals of Internal Medicine 148 (3): 169–77.
Paper not yet in RePEc: Add citation now
Yip, Winnie C. 1998. “Physician Response to Medicare Fee Reductions: Changes in the Volume of Coronary Artery Bypass Graft (CABG) Surgeries in the Medicare and Private Sectors.†Journal of Health Economics 17 (6): 675–99.